Do you know the five top pilot policies in the field of Chinese medicine?

In 2019, great changes have taken place in the field of medicine Both Chinese and foreign pharmaceutical enterprises have made major adjustments in resource allocation and human resources this year The most obvious influencing factor is the "4 + 7" national drug volume purchase policy pilot: the results of last year's "4 + 7" pilot selection will be implemented at the end of March this year, followed by the "4 + 7" national expansion, and the new results will be implemented next month However, there are still some factors that force pharmaceutical enterprises to urgently adjust the whole industry, change their traditional operation ideas, and respond to the new market environment with innovation and change "4 + 7" is just another hit this year We will find that since 2015, the state has promoted five national medical policy pilot projects in the field of Medicine: MAH pilot, two vote pilot, 4 + 7 pilot, DRGs pilot and Boao medical pilot in Hainan Reform and opening up for more than 40 years, during which a landmark language is "feeling the stones across the river." If the country wants to be strong, the industry needs to develop, and the river needs to cross, what can be done more safely? Touch the stone, keep balance, step by step, don't fall! When it comes to the pharmaceutical industry, the outside world often says that water depth! Is the water really deep? It's really not There are some unreasonable phenomena in the pharmaceutical industry Who doesn't know? Just a few things This is also illustrated by the implementation and effectiveness of the five top medical pilot policies So why are there so many years of resistance to medical reform? Of course, there are other reasons, but it is not because of the depth of water Want big Mi to say, can touch stone, explain most area is not water depth (cannot solve), but water mix (problem is complex)! Because the water is not deep, you can feel the stone Because the water is mixed, you need to touch the stone The reform logic of "crossing the river by feeling the stones" is to make more experiments and more summaries It is important to be stable, step by step In December 2012, general secretary Xi Jinping also pointed out that "crossing the river by feeling the stones" is a reform method with Chinese characteristics and in line with China's national conditions "When we studied collectively in the eighteen China's Political Bureau of the CPC Central Committee," To cross the river by touching a stone is to touch the law " He added: "today, we also need to take the method of pilot exploration and asking the way by throwing stones into the stone We have gained experience and formed a consensus We have seen it very accurately We feel that it is very stable to push it forward, and then push it forward to accumulate small victories to win big victories." The practice of "crossing the river by feeling the stones" is very pragmatic Those who enter the industry early should be familiar with the saying that "it is expensive to see a doctor, but it is difficult to see a doctor" 14 At all stages of the value chain, the medical system with a population of 100 million has always been faced with the problem of insufficient supply and demand We should take action to solve these problems, and avoid the unexpected impact It is a pragmatic and stable approach that we should carry out the pilot before the implementation of major policies nationwide, first touch the "stone" and then move forward With this in mind, we can easily understand the five national level pharmaceutical pilot policies in recent years From a global perspective, the consumption of mature drugs in emerging markets is large, but there is also a good profit margin Take our domestic example, both multinational pharmaceutical enterprises and local enterprises benefit from this We can see that in 2018, the policy environment and public opinion atmosphere for reducing drug prices in China are basically mature, and drug bidding and purchase, price management, and medical insurance fund payment are gradually straightened out At the same time, more importantly, the consistency evaluation of generic drugs has made significant progress, meeting the quality conditions of competition between Chinese and foreign pharmaceutical companies in the same platform The "4 + 7" pilot policy is the transfer of drug bidding from provincial standard to national standard When the data technology and public opinion environment are mature, the bidding and procurement will be further centralized to realize the price reduction idea of exchanging quantity for price On November 14, 2018, the fifth meeting of the national Deep Reform Commission deliberated and approved the pilot scheme of centralized drug procurement organized by the state, and 31 drug procurement documents were officially released for the first time The pilot areas include Beijing, Tianjin, Shanghai, Chongqing and 11 cities including Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xi'an (referred to as "4 + 7") On December 17, 2018, the state 4 + 7 urban pharmaceutical joint procurement office last night released the final version of the list of selected varieties of 25 varieties, as well as the list of supply varieties after the selection, which began to be implemented in April this year On March 20 of this year, after the first batch of 4 + 7 pilot cities began to implement the results of the selection, the "Butterfly Effect" appeared Next, many foreign enterprises successively reduced drug prices to gain access advantages Some domestic enterprises began to cancel costs, and enterprises reduced the 4 + 7 product promotion team After that, the "4 + 7" pilot was promoted to National Alliance procurement, expanding from 11 pilot cities to all provinces in the country On September 1 this year, the centralized procurement documents of drugs in the alliance area and the procurement volume of 25 varieties in each province were released, and the materials were submitted by the enterprises on the 24th of that month, and the results of the winning drug enterprises were announced on the 25th This time, because it is a nationwide recruitment, which has a greater impact on enterprises Many foreign enterprises began to make substantive structural adjustment, reduce the number of promotion personnel, and more domestic pharmaceutical enterprises directly disbanded the national promotion team According to industry rumors, the second round of 4 + 7 varieties is expected to start in April next year Many enterprises have begun to adjust more mature drug teams That is to say, the drug listing license holder system is an important part of the reform of our drug review and approval system The pilot of this system began in 2015 The system of drug listing license holder is a common practice in the field of drug supervision in developed countries and regions such as Europe, America and Japan The system adopts the management mode of separating drug listing license and production license, allowing drug listing license holders to produce drugs themselves or entrust other manufacturers to produce drugs Before that, our country implemented the management mode of integration of marketing license and production license for drugs, which is not conducive to the research and development of innovative drugs, but also causes the repeated construction, overcapacity and waste of the pharmaceutical industry The rapid development of China's pharmaceutical market needs a better drug evaluation system and the cooperation of pharmaceutical industry, so as to transform from a pharmaceutical power to a pharmaceutical power On November 5, 2015, the 17th meeting of the Standing Committee of the 12th National People's Congress decided to authorize pilot drug listing license holder system in ten provinces and municipalities directly under the central government, including Beijing, Tianjin, Hebei, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, Guangdong and Sichuan, to allow drug research and development institutions and researchers to obtain drug approval numbers and bear corresponding responsibilities for drug quality On June 6, 2016, the State Office officially released the pilot program of drug listing license holder system.